Key points are not available for this paper at this time.
Abstract Introduction Breast reduction surgery (BRS) is an oncoplastic method used for breast conserving surgery for breast cancer. The choice and timing of contralateral surgery is based on patient preference, risk factors and complications in relation to expected adjuvant treatment. Method Female patients who underwent BRS (unilateral or bilateral) for breast cancer between 2018-2022 were analyzed retrospectively regarding complications, reoperations and cosmetic outcome (Bcct.core Global assessment). Patient-reported outcome (BREAST-Q reduction module) was collected prospectively. Three groups; unilateral BRS (1), immediate bilateral breast surgery, at least one side BRS (2) and a later contralateral BRS (3) were compared using a nonparametric test with 0.05 significance level. Result Among eligible patients, 39 consented to inclusion (group 1 n=12, group 2 n=12, group 3 n=15). The mean age was 55 years, 97,5% were ASA class 1 or 2 and mean BMI was 26.8.There were two reoperations, one due to bleeding (group 3) and one for wound dehiscence (group 1). There were no statistical differences regarding complications, CCI was 5, 6.1 and 7.6 for group 1-3 respectively. The Bcct.core global assessment score was median “fair” (group 1) and “good” (group 2 and 3), with a significant difference between group 2 and 1. Satisfaction with breast (BREAST-Q) showed a median of 59 (all), with no group difference. Discussion No difference in complications or BREAST-Q score was seen between the groups. A significantly better aesthetic outcome was seen for immediate bilateral breast reduction surgery. This knowledge can add to the shared decision-making regarding oncoplastic breast reduction surgery for breast cancer patients.
Noorzaei et al. (Thu,) studied this question.